The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.“It is quite ...

An update on CAR-T therapies for MM and B-cell NHL presented at the 2026 ONA Summit highlighted the integral role of oncology nurses in ensuring patients achieve optimal outcomes.

Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...

Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy ...

The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 / uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) developmen ...

A fresh and important book reveals the messy reality of our ever-mutating cells – and why the quest to defeat ageing is ...

Experiments conducted in Brazil using laboratory rats have shown that graphene-based structures can act as a powerful ally in ...

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...

Preserve study integrity. Resist the temptation to bolt new exploratory endpoints midstream. If an additional endpoint is ...

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating ...